ALS stem cell study halted after just one patient
NCT ID NCT06910384
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a single dose of STR04, made from a patient's own bone marrow stem cells, for amyotrophic lateral sclerosis (ALS). Only one person enrolled before the study was stopped early. The goal was to see if the treatment was safe and could slow the disease, but no conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- autologous bone-marrow-derived mesenchymal stem cells
- What this could lead to
- If successful, this approach could point toward a treatment to slow ALS progression.
- What could go wrong
- The trial was terminated early with only 1 participant, so results are not reliable. Stem cell treatments for ALS remain unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Neuromuscular Research Institute
Austin, Texas, 78759, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a brain disease change behavior years before diagnosis?
- Can a cancer drug slow ALS? a trial aims to find out
- Can conversation unlock clues to ALS speech decline?
- Could a simple Pre-Tube ritual ease feeding problems in ALS?
- Can tracking brain changes over time unlock the secrets of frontotemporal dementia?
- A muscle test in the thigh may reveal how ALS attacks the body